32 completed, 9 approved for marketing, 7 terminated, 5 unknown. 20 Phase 2, 12 Phase 3, 8 Not applicable, 8 Phase 4, 4 Phase 1.
Follow fish oil triglycerides: new trials by email Literature Review of fish oil triglycerides trials Research Report on fish oil triglycerides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Fish Oil Emulsion in Critically Ill Patients With High Inflammatory Status. Omegaven (10% fish-oil emulsion; Fresenius-Kabi) - Critical Illness | Phase 2 | Recruiting | Lee Zheng Yii | 159 | 2026-07-07 | 2026-10-20 |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment Omegaven® (fish oil triglycerides) Injectable Emulsion - Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency | Recruiting | Fresenius Kabi | 40 | 2024-12-15 | 2026-08-14 | |
| Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients Fish Oil, Intravenous 0.9% Sodium Chloride - Intensive Care Unit, Coronary Artery Bypass Grafting (CABG) | Phase 2 | Recruiting | GCP-Service International West GmbH | 550 | 2024-02-15 | 2026-07-08 |
| Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC) Omegaven® (fish oil triglycerides) Injectable Emulsion - Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency | Withdrawn | Fresenius Kabi | 2022-04-01 | 2022-08-04 | ||
| Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - Omegaven®, Sodium chloride - COVID-19 | Phase 2 | Completed | Karolinska University Hospital | 23 | 2020-06-23 | 2022-01-05 |
| High Dose Intravenous Fish Oil Reduces Inflammation Omegaven - Lipid Metabolism Disorders | Completed | Stanley Dudrick's Memorial Hospital | 51 | 2020-01-31 | 2020-07-22 | |
| Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health Omegaven, Intralipid - Esophageal Atresia | Phase 2 | Withdrawn | Boston Children's Hospital | 2019-09-01 | 2019-09-16 | |
| Omegaven as Alternative Parenteral Fat Nutrition Omegaven - Cholestasis, Cholestasis of Parenteral Nutrition | Phase 3 | Completed | University of South Florida | 2 | 2018-10-23 | 2020-07-22 |
| Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation Omegaven, Soybean oil lipid emulsion - Hematopoietic Stem Cell Transplantation | Phase 1 | Completed | Alexandra N. Carey | 20 | 2016-06-01 | 2025-09-22 |
| Compassionate Use of Omegaven in Children Omegaven - Total Parenteral Nutrition-induced Cholestasis, Cholestasis | Phase 2 / Phase 3 | Completed | University of Oklahoma | 63 | 2015-06-01 | 2019-11-25 |
| Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function Omegaven, Placebo - Colon Cancer | Phase 4 | Completed | Medical Center Alkmaar | 44 | 2014-10-01 | 2018-07-31 |
| Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity Omegaven, Standard lipids (primarily omega-6 fatty acids) - Retinopathy of Prematurity | Phase 2 | Completed | University of California, San Diego | 48 | 2014-03-01 | 2022-12-29 |
| Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients OMEGAVEN, Daunorubicin, Cytarabine - Acute Myeloid Leukemia (AML) | Phase 2 | Completed | French Innovative Leukemia Organisation | 30 | 2013-11-01 | 2018-04-27 |
| Omegaven® as Parenteral Nutrition Omegaven - Cholestasis | Not applicable | Unknown | Carle Foundation Hospital | 25 | 2013-10-01 | 2015-01-08 |
| Fish OIL Optimal dosE Determination Study 0.20 gm/kg fish oil, 0.50 gm/kg fish oil - Sepsis | Phase 2 | Terminated | University Hospital Carl Gustav Carus | 7 | 2013-10-01 | 2017-04-19 |
| Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury Omegaven - Liver Disease, Impaired Liver Function | Not applicable | Completed | Children's Medical Center Dallas | 15 | 2013-08-01 | 2019-02-06 |
| Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection Omegaven™ - Major Liver Surgery | Phase 3 | Unknown | University of Zurich | 258 | 2013-07-01 | 2014-06-04 |
| Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease Omegaven - Parenteral Nutrition-related Hepatitis | Phase 2 / Phase 3 | Completed | Children's Mercy Hospital Kansas City | 2 | 2013-04-01 | 2021-06-11 |
| Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery MCT/LCT and fish oil, MCT/LCT - Gastric Tumor, Pancreatic Tumor | Phase 4 | Unknown | Wei Zhou | 50 | 2013-04-01 | 2013-03-28 |
| Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury Omegaven - Cancer, Hepatic Injury | Phase 2 | Terminated | Midwestern Regional Medical Center | 12 | 2012-10-01 | 2018-08-07 |
Showing 20 of 61. Sign in to see all of them.
Cholestasis (23) · Hyperphagia (13) · Short Bowel Syndrome (8) · Liver Diseases (7) · Stomach Neoplasms (5) · Malnutrition (4) · Intestinal Failure (3) · Atrial Fibrillation (2) · Infections (2) · Intestinal Atresia (2) · Pancreatic Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Premature Birth (2) · Sepsis (2) · Adenocarcinoma Of Esophagus (1)
Boston Children's Hospital (2) · Fresenius Kabi (2) · Jagiellonian University (2) · University of California, San Diego (2) · University of Nebraska (2) · Aalborg University Hospital (1) · Alexandra N. Carey (1) · Arthur J De Lorimier (1) · Baylor College of Medicine (1) · Carle Foundation Hospital (1) · Catherine Cibulskis, MD (1) · Centre Hospitalier Universitaire Vaudois (1) · Children's & Women's Health Centre of British Columbia (1) · Children's Hospital Los Angeles (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (31) · Poland (4) · Switzerland (3) · Canada (2) · China (2) · Germany (2) · Netherlands (2) · Turkey (Türkiye) (2) · Austria (1) · Czechia (1) · Denmark (1) · France (1) · Malaysia (1) · Russia (1) · Sweden (1)
Alexandra N Carey, MD (1) · Aloka L Patel, MD (1) · Avash J Singh, MD (1) · Axel R. Heller, MD (1) · Bankole O Osuntokun, MD, MS (1) · Boon-Siang Khor, MD (1) · Brian A Jones, MD (1) · Burkhard F Leeb, MD (1) · Christian Stoppe, Prof. Dr. (1) · Christopher Duggan, MD, MPH (1) · Cindy Haller, MD (1) · Cynthia Blanco, MD (1) · Daren Heyland, MD, PhD (1) · David F Mercer, MD, PhD (1)
PMID 32059815, PMID 33038344, PMID 34695449, PMID 18650630, PMID 19661785, PMID 20473991, PMID 21820770, PMID 23164314, PMID 23201707, PMID 23269816, PMID 23770843, PMID 23894176, PMID 23909727, PMID 24363760, PMID 25027101, PMID 25066733, PMID 26268565, PMID 27342748, PMID 28437326, PMID 28521607, PMID 29505137, PMID 29960156, PMID 30142422, PMID 30411372, PMID 30900274, PMID 31626819, PMID 31826232, PMID 32072161, PMID 33505321, PMID 35697729